KCFB

KCFB is a privately owned Swiss biotechnology company specializing in regenerative medicine and tissue engineering. Established in 2019, the company focuses on the creation and delivery of innovative clinical treatments for chronic wounds, such as chronic lower limb ulcers (CLLU) and bedsores. KCFB's proprietary, patented technology platform utilizes human cells (specifically allogeneic fibroblasts) as biocarriers of alarmins, including HMGB1 group proteins, to restore the normal microenvironment of chronic wounds and activate the healing process. Its lead Advanced Therapy Medicinal Product (ATMP), FBPlus, is classified as a Tissue Engineering Product by the European Medicines Agency (EMA). KCFB operates in Italy through its subsidiary, HMG Biologics.